Black, Hispanic, and Asian patients with large B-cell lymphomas are significantly less likely to receive potentially life-saving CAR T-cell therapy compared to White patients, according to a recent study by Dr. Samer Al Hadidi from the University of Arkansas for Medical Sciences.
The retrospective analysis, presented at the 2022 American Society of Clinical Oncology Annual Meeting, found that out of 1,405 patients, only 25 (1.8%) were Black, 45 (3.2%) were Hispanic, and 40 (2.8%) were Asian.
Dr. Al Hadidi emphasized the need to address these disparities, stating that efforts should focus on improving access to care, clinical trial enrollment, and patient education. He also highlighted the importance of diversifying the healthcare workforce and addressing social determinants of health.
The study underscores the persistent racial and ethnic disparities in access to advanced cancer treatments like CAR T-cell therapy. Experts call for a multifaceted approach to bridge these gaps, including increased funding for research, community outreach, and policies that promote health equity.
As CAR T-cell therapy continues to show promise in treating various blood cancers, ensuring equal access to this innovative treatment remains a critical challenge in the fight against cancer disparities.
“Addressing Disparities in CAR T-Cell Therapy Access for Minority Patients with Large B-Cell Lymphomas” (April 8, 2024)
